

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



136

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12Q 1/70, C12N 7/06</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/18969</b> <b>(43) International Publication Date:</b> 6 April 2000 (06.04.00)
<b>(21) International Application Number:</b> PCT/US99/21245 <b>(22) International Filing Date:</b> 22 September 1999 (22.09.99) <b>(30) Priority Data:</b> 09/161,030 25 September 1998 (25.09.98) US <b>(71) Applicant:</b> PENTOSE PHARMACEUTICALS, INC. [US/US]; 45 Moulton Street, Cambridge, MA 02138 (US). <b>(72) Inventors:</b> EDSON, Clark, McWhorter, 3 Durham Street #2, Somerville, MA 02143 (US). PURMAL, Andrei, A.; 58 Jacqueline Road #11, Waltham, MA 02452 (US). ACKERMAN, Samuel, K.; 175 King's Grant Road, Weston, MA 02493 (US). <b>(74) Agent:</b> CLARK, Paul, T.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHODS TO SELECTIVELY INACTIVATE VIRUSES IN BIOLOGICAL COMPOSITIONS  <b>(57) Abstract</b>  The invention features a method for inactivating animal viruses in a preparation of purified mammalian cells which, when mature, lack a nucleus (e.g., red blood cells or platelets), that includes contacting the preparation with a selective ethyleneimine oligomer inactivating agent under viral inactivating conditions for a period of time sufficient to inactivate at least some of the animal viruses in the preparation. Also disclosed is a method for removing the ethyleneimine oligomer inactivating agent from a treated biological composition, following viral inactivation without the addition of any quenching agent.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

PATENT  
ATTORNEY DOCKET NO: 50005/011WO1

METHODS TO SELECTIVELY INACTIVATE VIRUSES  
IN BIOLOGICAL COMPOSITIONS

5

Background of the Invention

This invention relates to methods and compositions for the selective inactivation of animal viruses in biological compositions, such as blood.

Following traumatic injury (or during surgery), an organism may require a blood transfusion to prevent death due to blood loss. In humans and certain  
10 domesticated animals, blood transfusion has enabled the survival of injured individuals who would otherwise have died from blood loss.

Whole blood is composed of many different types of proteins and cells. Blood proteins include antibodies, complement proteins, and proteins involved in the blood clotting cascade. In addition, each of the different types of blood  
15 cells plays a unique role in maintaining the health of the organism. Red blood cells, for instance, are essential for the transport of oxygen and carbon dioxide gases to and from the cells of a multicellular organism. Another type of blood cell, a platelet, is involved in initiating blood clotting; thrombocytopenia patients have a platelet deficiency and are prone to bleeding disorders.

20 One caveat in using blood transfusions is the danger of transmitting blood-borne viruses from donor blood to a recipient. The transmission of viral diseases (e.g., hepatitis A, B, and C, acquired immunodeficiency syndrome, and cytomegalovirus infections) by blood or blood products is a significant problem in medicine. Screening donor blood for viral markers can help reduce the  
25 transmission of viruses to recipients, but many screening methods are directed to only a few discrete viruses and are therefore incomplete or less than 100% sensitive.

A number of agents have been developed that are capable of inactivating viruses found in blood, as well as viruses found in other biological

-2-

compositions, such as mammalian and hybridoma cell lines, products of cell lines, milk, colostrum, urine, and sperm. For example, ethyleneimine monomer and ethyleneimine oligomers are very effective viral inactivating agents. These agents are themselves toxic, and must therefore be rendered non-toxic before a product, such as blood or milk proteins, may be used clinically. Typically, a viral inactivating compound, such as ethyleneimine dimer, is added to a biological composition to inactivate infectious viruses that might be present in the composition. A quenching agent is then added to inactivate the ethyleneimine dimer that remains after viral inactivation has taken place. The end result is a biological composition that is relatively free of infectious viruses, but that is contaminated with quenched inactivating agent and with quenching agent.

#### Summary of the Invention

In general, the present invention features a method for inactivating viruses in purified mammalian a-nucleated cell preparations, and a method for removing a virus inactivating agent from a treated biological composition by washing with an inert solution.

Accordingly, in a first aspect, the invention features a method of inactivating animal viruses in a preparation of purified mammalian a-nucleated cells that includes contacting the preparation with a selective ethyleneimine oligomer inactivating agent under viral inactivating conditions for a period of time sufficient to inactivate at least some of the animal viruses in the preparation.

In various embodiments of the first aspect of the invention, the cells are red blood cells or platelets, and the ethyleneimine oligomer is PEN102. In other embodiments, at least 90% of the animal viruses in the preparation are inactivated, or preferably at least 98% of the animal viruses in the preparation

-3-

are inactivated. In another embodiment, the mammalian cell is from a mammal that is a human, a non-human primate, a domesticated mammal, or an endangered mammal.

5 In another embodiment of the first aspect, the method further includes washing the contacted preparation with a solution that does not quench the ethyleneimine oligomer, where the washing reduces the concentration of the ethyleneimine oligomer in the washed preparation. Preferably, the concentration of the ethyleneimine oligomer in the washed preparation is at or below a concentration of the ethyleneimine oligomer that is toxic. In other  
10 embodiment, the solution is sterile unbuffered saline and the washing is manual.

In another embodiment of the first aspect, the washing includes the steps of: (i) layering the contacted preparation on a mesh having pores with diameters smaller than the diameters of the a-nucleated cells; and (ii)  
15 continuously flowing the solution that does not quench the ethyleneimine oligomer over the contacted preparation. In yet another embodiment, the washing includes the steps of: (i) adding a volume of the solution that is at least three times the volume of the preparation; and (ii) removing the solution from the preparation. Preferably, the washing is repeated at least two times.

20 In another embodiment of the first aspect, the washing is automated. Preferably, in the washing process, a container containing the contacted preparation is in a machine that performs the following steps under sterile conditions: (i) pumping the preparation out of the container; (ii) diluting the preparation with the solution that does not quench the ethyleneimine oligomer;  
25 (iii) removing the solution from the preparation, wherein the solution is discarded; and (iv) pumping the preparation back into the container. Preferably, the machine performs steps (ii) and (iii) at least two times.

In another embodiment of the first aspect of the invention, the method

-4-

further includes quenching the contacted preparation with a quenching agent. The quenching agent may be soluble or may be immobilized on a solid-phase support.

5 In a second aspect, the invention features a method for selectively inactivating animal viruses in a biological composition that includes the steps of: (a) contacting the composition with a selective ethyleneimine oligomer inactivating agent under viral inactivating conditions for a period of time sufficient to inactivate at least some of the animal viruses in the composition; and (b) washing the composition with a solution that does not quench an  
10 ethyleneimine oligomer, wherein the washing reduces the amount of the ethyleneimine oligomer in the composition. Preferably, the concentration of the ethyleneimine oligomer in the washed composition is at or below a concentration of the ethyleneimine oligomer that is toxic. In various embodiments, the solution is sterile unbuffered saline and the washing step is  
15 automated.

In yet another embodiment of the second aspect of the invention, in the washing step, a container containing the contacted composition is in a machine that performs the following steps under sterile conditions: (i) pumping the composition out of the container; (ii) diluting the composition with the solution  
20 that does not quench the ethyleneimine oligomer; (iii) removing the solution from the composition, wherein the solution is discarded; and (iv) pumping the composition back into the container. Preferably, the machine performs steps (ii) and (iii) at least two times.

25 In yet another embodiment of the second aspect, the washing step includes: (i) adding a volume of the solution that is at least three times the volume of the composition; and (ii) removing the solution from the composition. Preferably, the washing step is repeated at least two times.

In various other embodiments of the second aspect, the composition


-5-

includes a mammalian cell and the washing step includes: (i) layering the contacted composition on a mesh having pores with diameters smaller than the diameter of the mammalian cell; and (ii) continuously flowing the solution that does not quench the ethyleneimine oligomer over the contacted composition.


- 5 The mammalian cell may be an a-nucleated cell (e.g., a platelet or a red blood cell). In other embodiments, the composition is a cell-free composition and the washing step is manual.

By "purified" is meant a preparation that contains, by volume, at least 50%, more preferably, at least 70%, more preferably at least 85%, even more preferably at least 95%, and most preferably, at least 98% of the indicated component. For example, a purified preparation of red blood cells contains at least 50% by volume red blood cells.

By "ethyleneimine oligomer" is meant a compound having (1) an aziridino moiety or a halo-hydrocarbon-amine moiety, and, preferably, (2) two or more nitrogen atoms separated by hydrocarbon moieties. These compounds are also referred to as "inactivating agents," or "selective inactivating agents." One preferred ethyleneimine oligomer of the invention is PEN102, which has the following formula:



A second preferred ethyleneimine oligomer of the invention is PEN103, which has the following formula:



An inactivating agent has "selectivity" for nucleic acids or "selectively"

-6-

reacts with nucleic acids if the comparative rate of reaction of the inactivating agent with nucleic acids is greater than the rate of reaction with other biological molecules, *e.g.*, proteins, carbohydrates or lipids.

5 By "nucleic acid" is meant both DNA and RNA, both single and double stranded.

"Inactivating," "inactivation," or "inactivate," when referring to nucleic acids, means to substantially eliminate the template activity of DNA or RNA, for example, by destroying the ability to replicate, transcribe or translate a message. For example, the inhibition of translation of an RNA molecule can be  
10 determined by measuring the amount of protein encoded by a definitive amount of RNA produced in a suitable *in vitro* or *in vivo* translation system. When referring to viruses, the term means diminishing or eliminating the number of infectious viral particles measured as a decrease in the infectious titer or number of infectious virus particles per ml. Such a decrease in infectious virus  
15 particles is determined by assays well known to a person of ordinary skill in the art.

"Viral inactivating conditions" refers to the conditions under which the viral particles are incubated with the selective ethyleneimine oligomer inactivating agents of this invention, including, for example, time of treatment,  
20 pH, temperature, salt composition and concentration of selective inactivating agent so as to inactivate the viral genome to the desired extent. Viral inactivating conditions are selected from the conditions for selective modification of nucleic acids described in U.S. Patent Application Serial No. 08/855,378, hereby incorporated by reference.

25 By "inactivate at least some of the animal viruses" is meant that at least 50% of the viruses in the treated preparation are inactivated, preferably at least 70% of the viruses are inactivated, more preferably at least 80%, still more preferably at least 90%, still more preferably at least 95%, still more preferably,



-7-

at least 99%, and most preferably, 100% of the viruses in the treated preparation are inactivated. The number of viruses in a preparation may be measured by the number or titer of infectious viral particles per ml of preparation. Such a measurement may be accomplished by a variety of well known virus titer assays.

By "animal virus" is meant a virus capable of infecting a cell from an animal. Animal viruses may be DNA or RNA viruses, and may be enveloped or non-enveloped viruses or viroids. Examples of animal viruses include, without limitation, poxviruses, herpes viruses, adenoviruses, papovaviruses, parvoviruses reoviruses, orbiviruses, picornaviruses, rotaviruses, alphaviruses, rubiviruses, influenza viruses, type A and B, flaviviruses, coronaviruses, paramyxoviruses, morbilliviruses, pneumoviruses, rhabdoviruses, lyssaviruses, orthomyxoviruses, bunyaviruses, phleboviruses, nairoviruses, hepadnaviruses, arenaviruses, retroviruses, enteroviruses, rhinoviruses and the filoviruses. Specifically excluded from the definition of an animal virus are viruses which infect non-animal cells (*e.g.*, a bacteriophage which infects bacterial cells).

By "biological composition" is meant a composition containing cells or a composition containing one or more biological molecules, or a composition containing both cells and one or more biological molecules. Cell-containing compositions include, for example, mammalian blood, red cell concentrates, platelet concentrates, leukocyte concentrates, blood plasma, platelet-rich plasma, semen, placental extracts, mammalian cell culture or culture medium, products of fermentation, and ascites fluid. Biological compositions may also be cell-free, and contain at least one biological molecule. By "biological molecule" is meant any class of organic molecule normally found in living organisms including, for example, nucleic acids, polypeptides, post-translationally modified proteins (*e.g.*, glycoproteins), polysaccharides, and lipids. Biological molecule-containing biological compositions include, for

-8-

example, serum, blood cell proteins, blood plasma concentrate, blood plasma protein fractions, purified or partially purified blood proteins or other components, a supernatant or a precipitate from any fractionation of the plasma, purified or partially purified blood components (*e.g.*, proteins or lipids),  
5 mammalian colostrum, milk, urine, saliva, a cell lysate, cryoprecipitate, cryosupernatant, or portion or derivative thereof, compositions containing proteins induced in blood cells, and compositions containing products produced in cell culture by normal or transformed cells (*e.g.*, via recombinant DNA or monoclonal antibody technology).

10 By an "a-nucleated cell" is meant a cell which, when mature, lacks a nucleus. Preferred examples of a-nucleated cells are platelets and red blood cells.

By a "solution that does not quench an ethyleneimine oligomer" is meant a solution that does not contain a quenching agent (*e.g.*, a thiophosphate or a thiosulfate). A quenching agent, when contacted with an ethyleneimine  
15 oligomer, renders the contacted ethyleneimine oligomer non-toxic. Preferred solutions that are incapable of reacting with an ethyleneimine oligomer are unbuffered saline and water.

By a "quenching agent" is meant a thiophosphate or a thiosulfate, or a  
20 compound containing a thiophosphate or a thiosulfate that, when contacted with an ethyleneimine oligomer, is capable of rendering the contacted ethyleneimine oligomer non-toxic.

By "domesticated mammal" is meant any non-human mammal that a human maintains. For example, cows, donkeys, mules, elephants, horses,  
25 llamas, camels, goats, sheep, reindeer, dogs, cats, pigs, ferrets, rabbits, mice, rats, hamsters, and guinea pigs are domesticated animals. In addition, any mammal that a human keeps as a pet, such as a pet skunk or a pet wolf, is also a domesticated mammal.

By "an endangered mammal" is meant a mammal that is included on the Endangered Species List compiled by the U.S. Fish and Wildlife Service as of September 25, 1998.

Currently, red blood cell preparations are used to transfuse a recipient,  
5 without prior inactivation of viruses. Hence, the methods and compositions of the present invention allow the inactivation of viruses in red blood cell preparations prior to their use in transfusions. As the inactivating agents described herein are selective for the nucleic acids that are a major component of viruses, viral nucleic acid can be selectively inactivated over the other  
10 molecules (e.g., proteins and lipids) present in the red blood cell preparation.

In addition, the invention features an *in vitro* method for removing an ethyleneimine oligomer from a biological composition following virus inactivation without using a quenching agent. This method results in a biological composition that is relatively free not only of contaminating viruses,  
15 but also relatively free of quenched (i.e., non-toxic) ethyleneimine oligomer and unreacted quenching agent.

Other features and advantages of the invention will be apparent from the following description and from the claims.

#### Brief Description of the Drawings

20 Fig. 1 is a schematic diagram showing the chemical reactions that take place during the post-column derivatization of PEN102 or quenched PEN102.

Fig. 2 is a schematic flow diagram showing the post-column reaction hardware used in the HPLC analysis of ethyleneimine oligomers.

Fig. 3 is the HPLC elution profile of PEN102.

25 Fig. 4 is a bar graph showing the distribution of PEN102 between the red blood cell component and the plasma component of fresh baboon whole blood (spun hematocrit (HCT) of 38%) following treatment with 12 mM (1000

-10-

µg/ml; 0.1% v/v) PEN102 for 6 hours at 20°C.

Fig. 5 is a bar graph showing the effectiveness of manual washing of PEN102 from the red blood cell fraction of whole baboon blood (spun HCT 38%) following treatment with 12 mM PEN102 for 6 hours at 20°C. The number of manual washes of the RBC fraction with nonbuffered saline (1:10 v/v) for 10 min. at 20°C is indicated, and residual PEN102 in the RBC fraction is shown as a percentage.

Fig. 6 is a bar graph showing the effectiveness of manual washing of PEN102 from the red blood cell fraction of whole baboon blood (SPUN HCT 38%) following treatment with 1000 µg/ml PEN102 for 6 hours at 20°C. The number of manual washes of the RBC fraction with nonbuffered saline (1:10 v/v) for 10 min. at 20°C is indicated, and residual PEN102 in the RBC fraction is shown as µg of PEN102 per ml of RBC.

Fig. 7 is a bar graph showing the quenching of the ethyleneimine dimer PEN102 (6mM) from human blood (plasma (gray bar) and red blood cells (black bar)) following incubation for 2 hours at 23°C with either 50 mM Na-thiosulfate or an equimolar amount of AgroPore-Thiophosphate solid-phase (a solid-phase quencher containing thiophosphomonoester groups).

#### Detailed Description

We have discovered a method to selectively inactivate viruses in a-nucleated cell preparations by treating the preparations with ethyleneimine oligomer inactivating agents. For example, most mature mammalian red blood cells, unlike those of other vertebrate animals, lack nuclei and, hence, lack nucleic acid. Thus, treatment of the cells with an ethyleneimine oligomer inactivating agent that inactivates nucleic acids allows for the selective inactivation of the nucleic acid of any viruses contaminating the red blood cell preparation, while leaving the red blood cells unaffected. Accordingly, as we demonstrate below, ethyleneimine oligomer-mediated inactivation of nucleic

-11-

acids in red blood cell preparations does not affect the *in vivo* longevity of the cells. Likewise, since mature platelet cells (also known as platelets) lack nuclei, they are similarly unaffected by treatment with virus-inactivating ethyleneimine oligomers.






5           The invention also provides a method for removing the ethyleneimine oligomer from the treated biological composition (*e.g.*, blood), prior to use of the composition by repeatedly washing the composition with a solution that does not quench the ethyleneimine oligomer (*e.g.*, sterile unbuffered saline). Where the biological composition is a composition containing cells (*e.g.*,  
10 sperm), the treated cells may be washed by repeated steps of resuspension in a solution that does not quench an ethyleneimine oligomer and isolating the cells by centrifugation. Where the biological composition is a cell-free composition (*e.g.*, milk), the treated milk proteins may be, for example, diluted with a solution that does not quench an ethyleneimine oligomer, and then dialyzed to  
15 remove the ethyleneimine oligomer.

          Thus, unlike the current methods which inactivate ethyleneimine oligomer in a treated biological composition with a quenching agent, leaving the biological composition contaminated with the quenched ethyleneimine oligomer and extraneous quenching agent, the method of the present invention  
20 allows the generation of a biological composition free of both virus and quenching agent.

#### Ethyleneimine oligomers

          The ethyleneimine oligomer inactivating agents of the present invention are compounds having (1) an aziridino moiety or a halo-hydrocarbon-amine  
25 moiety, and, preferably, (2) two or more nitrogen atoms separated by hydrocarbon moieties. For example, an ethyleneimine oligomer may have one of the following five formulas:

-12-




Ethyleneimine oligomers can also be substituted so long as this does not eliminate the essential property of the ethyleneimine (*i.e.*, the inactivation of nucleic acids). In one variation, the ethyleneimine oligomers are substituted with halogens and have the general formula  $\beta\text{-Hal-(CH}_2\text{-CH}_2\text{-NH)}_n\text{H}$ .

20 Preferably, the "n" is an integer between 2-5, inclusive.

The ethyleneimine oligomer inactivating agents of the present invention also include both aziridino compounds and halo-hydrocarbon-amine compounds.

The aziridino compounds have the formula:



-13-

where each of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_6$ ,  $R_7$ , and  $R_8$  is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_6$ ,  $R_7$ , and  $R_8$  cannot all be H;  $R_5$  is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive. These compounds can be prepared by the aziridine-initiated oligomerization of a halo-hydrocarbon-amino compound.

The halo-hydrocarbon-amine compounds can have the formula  $\omega\text{-X}_1\text{-}[\text{R}_1\text{-N}^+(\text{R}_2, \text{R}_3)\text{-}]_n\text{R}_4\text{-(X}_2\text{)}_n$ , where  $X_1$  is Cl or Br;  $R_1$  is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; each of  $R_2$ ,  $R_3$ , and  $R_4$  is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that  $R_2$ ,  $R_3$ , and  $R_4$  cannot all be H when  $R_1$  contains 2 carbon atoms;  $X_2$  is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive. These compounds can be prepared by the oligomerization of the corresponding halo-hydrocarbon-amino compounds.

Alternatively, these compounds can have the formula  $\beta\text{-X}_1\text{-CH}_2\text{CH}_2\text{-N}^+\text{H(R}_1\text{)-}[\text{R}_2\text{-N}^+(\text{R}_3, \text{R}_4)\text{-}]_n\text{R}_5\text{-(X}_2\text{)}_{n+1}$ , where  $X_1$  is Cl or Br; each of  $R_1$ ,  $R_3$ ,  $R_4$ , and  $R_5$  is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive;  $R_2$  is a divalent hydrocarbon moiety having 3 or 4 carbon atoms;  $X_2$  is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive. These compounds can be prepared by the aziridine-initiated oligomerization of an halo-hydrocarbon-amino compound, followed by conversion of the aziridino group to the corresponding halide compound.

Methods for producing and using ethyleneimine oligomers for inactivating viruses in biological compositions are generally described in U.S. Application Serial Nos. 08/835,446 (filed April 8, 1997), 08/521,245 (filed

-14-

August 29, 1995), 08/855,378 (filed May 13, 1997), 09/005,606 (filed January 12, 1998), and 09/005,719 (filed January 12, 1998), hereby incorporated by reference.

#### A-Nucleated Cell Preparation

5           Since the goal of a blood transfusion is often the transfer of red blood cells, it may be desirable to separate these cells from the other blood components, such as white blood cells (*e.g.*, lymphocytes, neutrophils, and platelets) and biological molecules (*e.g.*, clotting factors and complement). In one example, prior to transfusion, whole blood may be separated into the  
10 following components: (1) the red blood cell (RBC) portion (which includes a small portion of the white blood cells) and (2) the plasma (which also includes a small portion of the white blood cells).

Standard methods exist for the separation of red blood cells from other blood components. For example, a Ficoll or Percoll gradient may be used to  
15 separate the different components of whole blood based on their differences in density. Such gradients may be generated using reagents commercially available from, for example, Pharmacia Biotech (Uppsala, Sweden).

In addition, commercially available systems, such as the MCS®+ Apheresis System (commercially available from Haemonetics Corp., Braintree,  
20 MA) may be used to isolate red blood cells from whole blood. It should be noted that this system may also be used to separate other a-nucleated cells (*e.g.*, platelet cells) from whole blood.

#### Removal of an ethyleneimine oligomer compound from a treated biological composition

25           Although ethyleneimine oligomers are useful compounds for the selective inactivation of viral nucleic acids, their inherent alkylating abilities



-15-

may render them toxic to most nucleated cells. Thus, prior to introduction of the treated red blood cells into the recipient animal, it is desirable to remove the ethyleneimine oligomer from the cells, or at least reduce the concentration of the ethyleneimine oligomer to a level that is non-toxic. Of course, if the cells  
5 or biological molecules are to be used *in vivo*, the washing step, in addition to the ethyleneimine oligomer treatment step, must be conducted under sterile conditions.

We have employed a murine lymphoma mutagenesis assay to detect toxic (*i.e.*, mutagenic) levels of the ethyleneimine oligomers and have found  
10 that the toxic level for the ethyleneimine oligomer used in the studies described below, PEN102, is greater than 1 µg/ml (*i.e.*, a concentration of 1 µg/ml PEN102 or less is non-toxic). The toxic levels of other ethyleneimine oligomers may be readily assessed using the murine lymphoma mutagenesis assay. Hence, the goal of the washing step is to reduce the concentration of the  
15 ethyleneimine oligomer in the desired treated biological composition to a level at or below that determined to be non-toxic.

One method to remove ethyleneimine oligomer compounds from a treated red blood cell preparation is to subject the cells to repeated washings with nonbuffered sterile saline (*i.e.*, sterile 0.9% NaCl). Following each  
20 washing step, a sample of the biological composition being treated (and washed) may be tested for the presence of the ethyleneimine oligomer at a concentration higher than that previously determined to be toxic. If the concentration is found to be at a toxic level, at the very minimum, at least one additional washing step should be performed prior to the *in vivo* use of the  
25 treated composition. As a safety measure, once a non-toxic level of an ethyleneimine oligomer is achieved, an additional washing step is preferably performed prior to the *in vivo* use of the treated composition.

In one example of washing red blood cells (RBCs) following treatment

-16-

of whole blood, the treated whole blood is diluted with approximately 3X volume of sterile 0.9% NaCl (*i.e.*, 15 ml saline is added to 5 ml blood). Following centrifugation to isolate the RBC component, the packed RBC volume is resuspended in approximately 9X volume of sterile 0.9% NaCl, and  
5 allowed to mix (under gentle mechanical agitation) for 10 minutes at 22°C. The RBC component is then isolated by centrifugation, and the washing step with 9X volume of sterile saline is repeated until the concentration of the ethyleneimine oligomer in the RBC component is at or below the concentration determined to be non-toxic (as determined, for example, using the mouse  
10 lymphoma mutagenicity assay described below).

In a second example, isolated platelets (isolated using, for example, plateletpheresis at a standard blood bank facility), are treated with a concentration of ethyleneimine oligomer for an amount of time and at an incubation temperature sufficient to inactivate at least some of the viruses in the  
15 platelet preparation. The platelets are next repeatedly washed in at least 4X volume of sterile saline solution until the concentration of the ethyleneimine oligomer is at or below the concentration determined to be non-toxic.

In another example, where the composition contains cells having a known diameter, the cells may be collected in mesh having pores of a diameter  
20 smaller than the cells' diameter, and then washed under a continuous flow of a solution that does not quench an ethyleneimine oligomer for a period of time sufficient to lower the concentration of the ethyleneimine oligomer in the cells to a non-toxic level. Of course, the fewer cells layered on the mesh, the lower the period of time necessary to wash the cells under a continuous flow. In a  
25 variation of this washing method, the ethyleneimine oligomer-treated cells may be collected in a mesh bag having pores of a diameter smaller than the cells' diameter. The bag may then be repeatedly dipped in a solution that does not quench the ethyleneimine oligomer until the concentration of the ethyleneimine

-17-

oligomer in the cells is reduced to a non-toxic level.

Although the washing steps described in the following examples are manual washings under sterile conditions, it will be understood that automated washing may be employed to free a biological composition from an  
5 ethyleneimine oligomer. For example, a machine may be designed to wash ethyleneimine oligomer treated cells under sterile conditions.

In one example of such a machine, purified platelets may be treated with ethyleneimine oligomer under viral inactivating conditions for a period of time sufficient to inactivate at least some of the viruses in the platelet preparation.  
10 This treatment step may be performed by combining the platelets with the ethyleneimine oligomer in a sterile container, such as a sterile plastic bag. The bag may then be attached to the machine such that machine can, under sterile conditions, pump the cells out of the bag (and, additionally rinse the bag with sterile 0.9% NaCl). Under completely sterile conditions, the machine may then  
15 dilute the platelets with sterile saline, gently mix the platelets for a desired time at a desired temperature, collect the platelets by centrifugation, discard the "used" sterile 0.9% NaCl, and add "fresh" 0.9% NaCl, and repeat the mixing-centrifugation-discarding process for a desired number of times. After the final collection of the platelets by centrifugation, the platelets may be resuspended in  
20 "fresh" 0.9% NaCl, or in another desired solution (*e.g.*, blood), and returned to the original container. Platelets thus virally inactivated and washed may be used immediately, stored, or frozen as desired.

#### Toxicity screening of an ethyleneimine oligomer

The same alkylating abilities of ethyleneimine oligomers that render  
25 them able to inactivate viral nucleic acids also enable them to damage and/or induce mutations in the genomic DNA of mammalian cells. Hence, before a ethyleneimine oligomer-treated biological composition may be used *in vivo* (or

*in vitro*, in, for example, the case of treated sperm for *in vitro* fertilization), it is desirable to reduce the concentration of the ethyleneimine oligomer in the composition to a level that is non-toxic to most mammalian cells.

The mouse lymphoma mutagenicity assay is one method to determine the toxicity concentration level of a particular ethyleneimine oligomer. This assay uses a murine lymphoma cell which is heterozygous at the thymidine kinase (TK) locus (*i.e.*, TK +/-) grown in the presence of the toxin, 5-trifluorothymidine (TFT), to screen different concentrations of the particular ethyleneimine oligomer. Both TK +/- cells and TK -/- cells are viable in normal culture media; however, in the presence of TFT, only the TK -/- cells will grow because the TK +/- cells will incorporate the toxic TFT into their DNA. If the TK +/- murine lymphoma cells are exposed to a toxic concentration of an ethyleneimine oligomer, they may undergo a single-step forward mutation to a TK -/- genotype, enabling them to grow in the presence of TFT. Thus, a concentration of an ethyleneimine oligomer which does not result in the growth of TK +/- murine lymphoma cells in the presence of 5-trifluorothymidine (TFT) is non-toxic.

The mutagenicity test we used below to screen the toxicity level of the ethyleneimine oligomer PEN102 was performed by Convance Laboratories Inc. (Vienna, VA). L5178Y murine lymphoma cells (which are heterozygous at the TK locus) grown in the presence of 5-trifluorothymidine (TFT) were exposed to different concentrations of PEN102. The results demonstrated that a concentration of 1 µg/ml PEN102 did not allow the growth (*i.e.*, the forward mutation) of L5178Y TK +/- cells in the presence of 5-trifluorothymidine (TFT). Hence, a concentration of less than or equal to 1 µg/ml PEN102 is non-toxic, and a PEN102-treated biological composition (*e.g.*, a treated RBC preparation) containing up to 1 µg/ml PEN102 is safe for infusion into a recipient.

High performance liquid chromatography (HPLC) analysis of ethyleneimine oligomer

Ethyleneimine oligomers are routinely analyzed by cation exchange HPLC. Because ethyleneimine oligomers do not contain a chromophore, the following method uses post-column derivatization which reacts only with primary amino groups, thereby eliminating complications of multiple reaction sites (ethyleneimine oligomers contain only one primary amino group) or interfering compounds. A schematic of the reactions that take place during HPLC of PEN102 and quenched PEN102 is shown on Fig. 1. The method has been determined to be linear within the range of 10-230 ng of PEN102.

a. Starting materials for HPLC analysis

A schematic diagram of the HPLC post column reaction hardware is shown on Fig. 2.

1. Potassium phosphate eluent, Pickering laboratories Catalog No.1700-1101; pH 6.00; 0.1 N. (Pickering Laboratories Inc., Mountain View, CA)
2. Potassium chloride eluent, Pickering Laboratories Catalog No. 1700-1102; pH 6.00; 0.1 N.
3. o-Phthalaldehyde (OPA) diluent, Pickering Laboratories Catalog No. OD104.
4. o-Phthalaldehyde (OPA), Pickering Laboratories Catalog No. O120.
5. Thiofluor, Pickering Laboratories Catalog No. 3700-2000.
6. Nitrogen, grade 4.8
7. *Equipment and conditions*
  - Beckman 126 solvent module (or equivalent); (Beckman Instruments Inc., Fullerton, CA)
  - Beckman Gold Nouveau software (or equivalent)
  - Jasco FP-920 intelligent Fluorescent detector (Jansco Inc., Easton, MD)

-20-

Pickering Laboratories PCX 3100 post-column reaction module

Alkion cation-exchange column 4 x 150 mm; Pickering Laboratories

Catalog No. 9410917

Excitation Wavelength. 330nm

5      Emission Wavelength: 465nm

Column temperature: 40°C

Reactor temperature: 45°C

Reactor pump flow rate: 0.3 ml/min.

b. Preparation of reagent solutions

- 10      1. Degas 450 ml OPA diluent for approximately 10 min. by bubbling  
nitrogen gas through the diluent.
2. Dissolve approximately 0.05 g o-phthalaldehyde (OPA) in a minimum  
amount of methanol, add to OPA diluent.
3. Dissolve approximately 1 g thiofluor in a small amount of OPA diluent,  
15      add to OPA solution from Step 2.

c. Protocol for HPLC analysis of PEN102

This method uses cationic exchange chromatography with post column  
derivatization of ethyleneimine oligomer primary amino groups and fluorescent  
detection. The HPLC elution profile of PEN102 is shown on Fig. 3.

- 20      1. Prepare samples in potassium phosphate eluent, pH 6. Dilute 1 µl  
PEN102 at a final concentration of  $1: 8 \times 10^4$  with the eluent.
2. Use potassium chloride eluent pH 6.
3. Inject 10 µl of the sample for analysis. Flow rate is set at 0.8 ml/min.
4. 0-4 min., 100% flow potassium phosphate eluent; 4-8 min., 0-100%  
25      flow potassium chloride eluent; 9-10 min., 100-0% flow potassium  
chloride eluent.
5. Reequilibrate the column with 100% potassium phosphate eluent for an  
additional 10 min. between analyses.

-21-

Since this method is very sensitive to contamination, gloves should be worn at all times when preparing buffers or samples.

The following specific examples are to be construed merely as illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Furthermore, although some of the examples describe the addition of the ethyleneimine oligomer to whole blood prior to the isolation of blood components, preferably the desired blood component (*e.g.*, red blood cells) is isolated prior to addition of the ethyleneimine oligomer. This not only reduces the amount of the ethyleneimine oligomer required to inactivate the viruses contained in the desired blood component, but also allows the retainment of other, untreated blood components (*e.g.*, plasma), which may be subsequently (or simultaneously) virally inactivated with an ethyleneimine oligomer. For example, virally inactivated plasma may be used to purify virus-free plasma proteins, such as blood clotting factors or albumin.

#### 15     Example I

##### Biochemistry of baboon RBCs treated with PEN102 or PEN103

Fifteen milliliters (ml) of fresh baboon blood was collected from baboon 205 (Naval Blood Research Laboratory) in CPD-ADSOL (a standard blood storage solution that prevents the blood from clotting). The fresh whole blood was treated with 0.79 ml of 240 mM PEN102 in 0.25 M  $\text{NaH}_2\text{PO}_4$  (20X stock solution of PEN102 was prepared immediately before the treatment). The final concentration of PEN102 in the blood was 12 mM (1000  $\mu\text{g/ml}$ ; 0.1% v/v). In a control experiment, 0.79 ml of 0.25 M  $\text{NaH}_2\text{PO}_4$  was added to 15 ml of fresh baboon blood. Both control and PEN102-treated samples were incubated, with rocking, for 6 hours at room temperature. After the end of the incubation period, the red blood cells were isolated by centrifugation, and a series of

-22-

biochemical parameters were immediately determined without removal of PEN102.

In addition, a parallel experiment was performed with a second ethyleneimine oligomer, PEN103. As above, fifteen milliliters (ml) of fresh  
5 baboon blood was collected from baboon 205 (Naval Blood Research Laboratory) in CPD-ADSOL. The fresh whole blood was treated with 0.79 ml of 310 mM PEN103 in 0.5 M  $\text{NaH}_2\text{PO}_4$  (20X stock solution of PEN103 was prepared immediately before the treatment). The final concentration of PEN103 in the blood was 15.5 mM (2000  $\mu\text{g}/\text{ml}$ ; 0.2% v/v). In a control  
10 experiment, 0.79 ml of 0.5 M  $\text{NaH}_2\text{PO}_4$  was added to 15 ml of fresh baboon blood. Both control and PEN103-treated samples were incubated, with rocking, for 6 hours at room temperature (*i.e.*, 22°C). After the end of the incubation period, the red blood cells were isolated by centrifugation, and a series of biochemical parameters were immediately determined without  
15 removal of PEN103.

Table I shows the results of the RBC biochemistry tests.



Table I  
 Biochemistry of CPD-ADSOL Baboon RBC Treated  
 With 12 mM PEN102 or 15.5 mM PEN103 for 6 Hours at 22°C

	pH 22°C (WB)	MOS mOs/kg	SUP HB (mg/dL)	HB (g/dL)	spun HCT	MCV (spun HCT)	MCHC (g/dL of RBC)	SUP K <sup>+</sup> (mEq/L)	Red Cell K <sup>+</sup> (meq/10 <sup>12</sup> RBC)	Red Cell Na <sup>+</sup> (meq/10 <sup>12</sup> RBC)	P50 (mmHg)	ATP (μmole/ gHb)
control	7.16	396	29	15.9	48	79	33	3.5	7.9	1.4	27.2	1.7
PEN102	7.16	404	25	16.1	48	78	34	3.6	7.9	1.2	29.1	1.7
PEN103	7.16	424	24	15.9	46	76	35	2.7	7.7	1.4	28.9	1.5

-24-

As can be seen from Table I, no significance difference was found between the control (*i.e.*, untreated), the PEN102-treated, or the PEN103-treated blood. Hence, treatment with PEN102 or PEN103 does not appear to affect the biochemical functioning of red blood cells.

5     **Example II**

Biochemistry and *in vivo* survival of PEN102 treated and washed baboon RBC

*Ila. Treatment of fresh CPD baboon blood with PEN102*

Eighty ml of fresh baboon blood collected from baboon 214 (Naval Blood Research Laboratory) in CPD (resulting in a spun HCT of 38%) was  
10     treated with 4.2 ml of 240 mM PEN102 in 0.25 M  $\text{NaH}_2\text{PO}_4$  (20X stock solution of PEN102 was prepared immediately before treatment). The final calculated total concentration of PEN102 in the blood was 12 mM (1000  $\mu\text{g/ml}$ ; 0.1% v/v).

*I Ib. Distribution of PEN102 between RBC and plasma in fresh whole CPD*  
15     *baboon blood.*

Following 6 hours of incubation of the blood at room temperature, the blood was separated into a plasma fraction and a red blood cell (RBC) fraction. The concentration of PEN102 in the plasma and RBC fractions was determined using the HPLC analysis described above.

20     The concentration of PEN102 in the plasma fraction was found to be 10.7 mM (893  $\mu\text{g/ml}$ ), while the concentration of PEN102 in the RBC fraction was only 5.6 mM (469  $\mu\text{g/ml}$ ). Therefore, after 6 hours of incubation, the RBC and plasma fractions of blood contained 24% and 76% of the total PEN102 respectively (Fig. 4).

-25-

*Iic. Manual washing of baboon RBC after PEN102 treatment.*

Eighty ml of treated baboon blood was divided in 6 portions (about 13 ml each) in 50 ml sterile tubes. The average volume of RBC in each portion was about 5 ml. Unbuffered sterile saline (*i.e.*, 0.9% NaCl in water) was added to fill each tube to about 50 ml. The RBC fraction was separated by centrifugation at 2000 rpm (1248 x g) for 5 min. at room temperature, and the diluted plasma fraction removed.

The RBC fraction was next subjected to a washing cycle: To the remaining RBC (about 5 ml in each tube), a new portion of unbuffered sterile saline (about 4.5 ml) was added. The tubes were incubated with gentle agitation at room temperature for 10 min. At the end of the incubation, RBC fraction was separated by centrifugation. After each cycle, a small aliquot of the RBC suspension was removed to determine the concentration of PEN102 by HPLC (see method above).

The washing cycle was repeated four times. After the fourth cycle, the six tubes of RBC were combined together and unbuffered sterile saline added to give a final hematocrit (HCT) of 46%. The effectiveness of the washing procedure is shown on Fig. 5, which demonstrates a rapid reduction in the percentage of PEN102 in the RBC fraction. The concentration of PEN102 remaining in the RBC fraction (in µg/ml of RBC) after each washing cycle is shown on Fig. 6. The data in Fig. 6 demonstrates that the residual concentration of PEN102 in the RBC after 4 washings was lower than the safety level for PEN102, 1 µg/ml, which was determined by mutagenicity testing on mouse lymphoma cells (performed by Covance, Vienna, VA).

*Iid. Biochemistry of baboon RBC after PEN102 treatment, washing, and storage for 18 hours.*

Washed, treated RBC (see section Iic above) were resuspended in 0.9%

-26-

saline-0.2% glucose to a hematocrit (HCT) of about 46%, and stored overnight (18 hours) at 4°C. Following storage, a series of biochemical parameters were determined. The results of biochemistry tests performed on these treated, washed, and stored RBC are presented in Table II.

5

**Table II**

**Biochemistry of Control (Untreated) and PEN102-treated,  
Washed, and Stored Baboon RBC**

	MOS mOs/kg	SUP HB (mg/dL)	HB (g/dL)	spun HCT	MCV (spun HCT)	SUP K <sup>+</sup> (mEq/L)	Red Cell K <sup>+</sup>	P50 (mmHg )	RBC pH	MCHC (spun HCT)
control*	394	3	12.6	38	80.9	3.5	7.9	31.8	6.939	29.0
10 PEN102 **	NA	90	13.3	46	91.1	2.2	8.0	30.6	6.649	32.0

\* fresh, untreated CPD baboon blood

\*\* baboon CPD blood, treated with PEN102, washed, and stored for 18 hours at 4°C

As shown in Figs. 5 and 6, four manual washing cycles of treated RBC effectively reduced the concentration of PEN102 below the level of safety determined in a companion mutagenicity study. Table II demonstrates that treatment of RBC with PEN102, followed by washing and 18 hours of storage at 4°C, did not affect the major biochemical characteristics of the RBC.

#### *Ile. Post-treatment in vivo survival of RBC.*

Five ml portions of PEN102 treated RBC from baboon 214 were labeled with either <sup>51</sup>Cr or biotin using standard labeling protocols (see, e.g., Valeri et al., Transfusion 24: 105-108, 1984). For example, to label RBCs with <sup>51</sup>Cr, approximately 20-30 ml of RBCs were incubated for 30 min. at 37°C with 0.5 µCi <sup>51</sup>Cr (disodium chromate) per ml of blood (commercially available from,

-27-

for example, Dupont/NEN, Boston, MA), and then washed to remove the unincorporated  $^{51}\text{Cr}$ -label. The RBCs were biotin-labeled using the Biotin-X-NHS kit, commercially available from Calbiochem (San Diego, CA). The  $^{51}\text{Cr}$ -labeled RBCs and biotin-labeled RBCs were then combined and infused back into baboon 214. Table II shows the *in vivo* survival time of the PEN102 treated, washed, and stored RBC compared to the *in vivo* survival time of normal RBCs that had been removed from baboon 214, labeled, and re-infused. The half-life (T50) of the RBCs is shown in days.

**Table III*****In vivo* Survival of RBC Post-PEN102 Treatment**

	T50 $^{51}\text{Cr}$	T50 biotin
Experimental	12.2 days	33 days
Historical for Baboon 214	13.8 days +/- 1.1 days	38 days +/- 5 days

As Table III demonstrates, the treatment of baboon RBC with 12 mM PEN102, followed by manual washing and storage of the RBC for 18 hours at 4°C, did not affect either the biochemistry or the lifespan of the RBC.

-28-

### Example III

#### Quenching ethyleneimine oligomer in treated human blood with Na-thiosulfate or a solid-phase quencher

In another method to remove the ethyleneimine oligomer from treated  
5 red blood cells, a quenching agent, either soluble (*i.e.*, Na-thiosulfate) or solid-  
phase, was used. The reagents and methods described in this example are  
described in more detail in Purmal et al., Solid Phase Quenching Systems, (U.S.  
Patent Application Serial No. 09/161,078, filed September 25, 1998).

In this experiment, 50  $\mu$ l of 120 mM PEN102 in 0.25 M  $\text{NaH}_2\text{PO}_4$  was  
10 added to 0.9 ml of whole human CPD blood (final concentration of PEN102  
was 6 mM, 6  $\mu$ mole total), and incubated at 23°C for 4 hours. At the end of the  
4-hour incubation period, 68 mg (50  $\mu$ mole-equivalents of  
phosphothiomonoester groups) of ArgoPore-Thiophosphate support was added.  
In the parallel experiment, 50  $\mu$ l of 1 M  $\text{Na}_2\text{S}_2\text{O}_3$  (final concentration 50 mM)  
15 was added to same amount of PEN102 treated blood. Both samples were  
allowed to incubate for 2 hours at 23°C. The red blood cell (RBC) and plasma  
fraction of the blood were separated by centrifugation (10,000 rpm, 5 min.),  
and the RBCs were opened by adding 9 volumes of water. The concentration  
of PEN102 was determined in RBC and in the plasma fraction of the blood by  
20 HPLC (Fig. 7).

As shown in Fig. 7, both sodium thiosulfate and solid phase-bound  
thiophosphate groups were capable of quenching PEN102. After 2 hours, the  
plasma quenched with sodium thiosulfate contained only 6.8  $\mu$ g/ml PEN102,  
and the red blood cells quenched with sodium thiosulfate contained 2.2  $\mu$ g/ml  
25 PEN102. The solid phase quencher containing thiophosphate groups was even  
more effective. The plasma quenched with this system contained only 1.5  
 $\mu$ g/ml PEN102, and the red blood cells contained only 0.9  $\mu$ g/ml PEN102 after  
2 hours. Thus, incubation of PEN102 treated red blood cells with the solid-

-29-

phase quencher for two hours lowered the concentration of PEN102 in the red blood cells to a non-toxic level.

#### Example IV

#### *In vivo* survival of ethyleneimine oligomer treated, washed, and frozen canine RBC

5           Blood is collect from a dog and divided into two portions. The first portion is incubated with an amount of ethyleneimine oligomer sufficient to inactivate at least some of the animal viruses in the portion. Following incubation, the red blood cells from this treated portion are isolated, washed  
10           four times with sterile unbuffered saline, as described above, and then frozen in glycerol for two weeks at -70°C.

          At the same time, the second portion is incubated for 6 hours at 22°C, but without any addition of ethyleneimine oligomer. Following incubation, the red blood cells are isolated and washed four times with sterile saline, and then  
15           frozen in glycerol for two weeks at -70°C.

          Following the two weeks of frozen incubation time, the cells are thawed. and cells in the first portion (*i.e.*, the ethyleneimine oligomer treated portion) are labeled with  $^{51}\text{Cr}$  while the cells in the second portion (*i.e.*, the untreated portion) are labeled with biotin. The cells are then combined and re-infused to  
20           the donor dog. The survival time of the  $^{51}\text{Cr}$  labeled red blood cells is compared to the survival time of the biotin-labeled cells, and no significant difference is predicted to be found between the two. Hence, ethyleneimine oligomer treatment does not affect the survival time of canine red blood cells *in vivo*.

Example V*In vivo* survival of PEN102 treated, washed, and frozen baboon platelets

Eighty ml of fresh baboon blood is collected from a baboon and the platelets are immediately separated from the remaining blood components (which are discarded). The purified platelets are divided into two equal portions, one of which (*i.e.*, the PEN102 treated portion) is treated for 6 hours at room temperature with 2.1 ml of 240 mM PEN102 in 0.25 M  $\text{NaH}_2\text{PO}_4$  (20X stock solution of PEN102 is prepared immediately before treatment) with the final calculated total concentration of PEN102 in the platelet-containing solution being 12 mM (1000  $\mu\text{g/ml}$ ; 0.1% v/v). The second portion (*i.e.*, the untreated portion) is treated for 6 hours at room temperature with 2.1 ml of a 0.25 M  $\text{NaH}_2\text{PO}_4$ .

The two portions of platelets are next separated by centrifugation, and the supernatant removed. The pelleted cells are next resuspended in sterile unbuffered saline, incubated at room temperature on a rocker for 10 min., and re-pelleted by centrifugation. After four cycles of this resuspension/re-pelleting, the platelets are frozen in glycerol for two weeks at  $-70^\circ\text{C}$ .

After two weeks, both the treated and the untreated portions of platelets are thawed and labeled with  $^{51}\text{Cr}$ , as described above. In a blind study, the  $^{51}\text{Cr}$  labeled PEN102 treated platelets are transfused into one recipient baboon and the  $^{51}\text{Cr}$  labeled untreated platelets are transfused into a second recipient baboon. Both of the recipient baboons are the same gender and roughly the same age. The T50 of the PEN102 treated platelets is predicted to be approximately equal to that of the untreated platelets.



Example VIBiochemistry and *in vivo* survival of ethyleneimine oligomer-treated, washed, and stored human RBC

Blood donated by a human blood donor is incubated with an amount of  
5 ethyleneimine oligomer sufficient to inactivate at least some of the animal  
viruses in the blood. Following incubation and using the MCS®+ Apheresis  
System (commercially available from Haemonetics Corp., Braintree, MA), the  
ethyleneimine oligomer treated blood is separated into three components: (1)  
the red blood cells (RBCs), (2) the platelets, and (3) the plasma. The plasma  
10 and platelets are frozen in glycerol and stored at -70°C.

The isolated RBCs are spread onto a mesh having pores with diameters  
that are smaller than the diameter of a human RBC, and rinsed with a  
continuous flow of sterile unbuffered saline until the concentration of  
ethyleneimine oligomer in the cells is at or below the concentration determined  
15 to be non-toxic in the mouse lymphoma forward mutation assay described  
above. The washed cells are next stored for 18 hours at 4°C. The sample of  
cells is then divided into two. The first of the two portions of washed, treated,  
and stored RBCs are subjected to testing for a series of biochemical parameters.  
No significant changes in the biochemical characteristics of the washed, treated  
20 RBC are predicted to be seen as compared to a sample of washed, untreated  
RBC.

The second of the two portions of washed, treated, and stored RBCs are  
labeled with biotin, and re-infused back into the same human donor. Tracking  
of the biotin-labelled cells demonstrates that the ethyleneimine oligomer treated  
25 cells survive *in vivo* for a length of time comparable that of untreated biotin-  
labeled red blood cells that are similarly isolated (*i.e.*, using the MCS®+  
Apheresis System), washed, and stored.

-32-

Example VIIProtein purification from ethyleneimine oligomer treated and washed bovine urine

5 A first sample of bovine urine is collected and incubated with an amount of an ethyleneimine oligomer sufficient to inactivate at least some of the viruses in the urine. Contemporaneously, a second sample of bovine urine is collected and subjected to the same incubation conditions as the first sample, but in the absence of any ethyleneimine oligomer. Both urine samples are next greatly diluted with sterile water until the concentration of the ethyleneimine oligomer is below that determined to be toxic in a mouse lymphoma mutagenicity assay (such as that described above and commercially performed by Covance, Vienna, VA).

10 The urine from both samples is then subjected to protein purification techniques to isolate the desired urine protein (e.g., the Tamm-Horsfall glycoprotein). Standard protein purification techniques include HPLC, and described in general technique laboratory manuals (see, e.g., Scopes, R. K., Protein Purification: Principles and Practice, ed. C. R. Cantor, Springer-Verlag Inc., New York, NY, 1982; Coligan, J.E., Current Protocols in Protein Science, John Wiley & Sons, New York, NY, 1996). A comparable amount of the desired urine protein is predicted to be purified from both the ethyleneimine oligomer treated urine and the untreated urine.

Other Embodiments

25 From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.

-33-

Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent  
5 publication or patent application was specifically and individually indicated to be incorporated by reference.

What is claimed is:

-34-

Claims

1. A method of inactivating animal viruses in a preparation of purified mammalian a-nucleated cells, said method comprising contacting said preparation with a selective ethyleneimine oligomer inactivating agent under viral inactivating conditions for a period of time sufficient to inactivate at least some of the animal viruses in said preparation.
2. The method of claim 1, wherein said cells are red blood cells.
3. The method of claim 1, wherein said cells are platelets.
4. The method of claim 1, wherein said ethyleneimine oligomer is PEN102.
5. The method of claim 1, wherein at least 90% of the animal viruses in said preparation are inactivated.
6. The method of claim 5, wherein at least 98% of the animal viruses in said preparation are inactivated.
7. The method of claim 1, wherein said mammal is selected from the group consisting of a human, a non-human primate, a domesticated mammal, and an endangered mammal.
8. The method of claim 1, wherein said method further comprises washing said contacted preparation with a solution that does not quench said ethyleneimine oligomer, wherein said washing reduces the concentration of said ethyleneimine oligomer in said washed preparation.

-35-

9. The method of claim 8, wherein said concentration of said ethyleneimine oligomer in said washed preparation is at or below a concentration of said ethyleneimine oligomer that is toxic.

5 10. The method of claim 8, wherein said solution is sterile unbuffered saline.

11. The method of claim 8, wherein said washing is manual.

12. The method of claim 8, wherein said washing comprises:

- 10 (i) layering said contacted preparation on a mesh having pores with diameters smaller than the diameters of said a-nucleated cells; and  
(ii) continuously flowing said solution that does not quench said ethyleneimine oligomer over said contacted preparation.

13. The method of claim 8, wherein said washing comprises the steps of:

- 15 (i) adding a volume of said solution that is at least three times the volume of said preparation; and  
(ii) removing said solution from said preparation.

14. The method of claim 13, wherein said washing is repeated at least two times.

15. The method of claim 8, wherein said washing is automated.

20 16. The method of claim 15, wherein in said washing process, a container containing said contacted preparation is in a machine that performs

*A method of transfer*

-36-

the following steps under sterile conditions:

- (i) pumping said preparation out of said container;
- (ii) diluting said preparation with said solution that does not quench said ethyleneimine oligomer;
- 5       (iii) removing said solution from said preparation, wherein said solution is discarded; and
- (iv) pumping said preparation back into said container.

17. The method of claim 16, wherein said machine performs steps (ii) and (iii) at least two times.

10       18. The method of claim 1, wherein said method further comprises quenching said contacted preparation with a quenching agent.

19. The method of claim 18, wherein said quenching agent is soluble.

15       20. The method of claim 18, wherein said quenching agent is immobilized on a solid-phase support.

21. A method for selectively inactivating animal viruses in a biological composition, said method comprising the steps of:

- (a) contacting said composition with a selective ethyleneimine oligomer inactivating agent under viral inactivating conditions for a period of time  
20       sufficient to inactivate at least some of the animal viruses in said composition;  
         and
- (b) washing said composition with a solution that does not quench an ethyleneimine oligomer, wherein said washing reduces the amount of said ethyleneimine oligomer in said composition.

-37-

22. The method of claim 21, wherein said concentration of said ethyleneimine oligomer in said washed composition is at or below a concentration of said ethyleneimine oligomer that is toxic.

5 23. The method of claim 21, wherein said solution is sterile unbuffered saline.

24. The method of claim 21, wherein said washing step is automated.

25. The method of claim 24, wherein in said washing step, a container containing said contacted composition is in a machine that performs the following steps under sterile conditions:

- 10 (i) pumping said composition out of said container;  
(ii) diluting said composition with said solution that does not quench said ethyleneimine oligomer;  
(iii) removing said solution from said composition, wherein said solution is discarded; and  
15 (iv) pumping said composition back into said container.

26. The method of claim 25, wherein said machine performs steps (ii) and (iii) at least two times.

27. The method of claim 21, wherein said washing step comprises:

- 20 (i) adding a volume of said solution that is at least three times the volume of said composition; and  
(ii) removing said solution from said composition.

28. The method of claim 27, wherein said washing step is repeated at

-38-

least two times.

29. The method of claim 21, wherein said composition comprises a mammalian cell.

30. The method of claim 29, wherein said washing step comprises:

- 5 (i) layering said contacted composition on a mesh having pores with diameters smaller than the diameter of said mammalian cell; and  
(ii) continuously flowing said solution that does not quench said ethyleneimine oligomer over said contacted composition.

10 31. The method of claim 29, wherein said mammalian cell is an a-nucleated cell.

32. The method of claim 31, wherein said mammalian cell is a platelet.

33. The method of claim 31, wherein said mammalian cell is a red blood cell.

15 34. The method of claim 21, wherein said composition is a cell-free composition.

35. The method of claim 21, wherein said washing step is manual.



1/5




Fig. 1

2/5




Fig. 2

3/5




Fig. 3




Fig. 4




Fig. 5




Fig. 6

5/5




Fig. 7

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/21245

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) :C12Q 1/70; C12N 7/06 US CL :435/5, 238 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/5, 238 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97/07674 A1 (PENTOSE PHARMACEUTICALS) 06 March 1997, the abstract; page 1 in its entirety; page 2, second paragraph;	1-3 & 5-7
-		---
Y	page 4, second paragraph, through page 6, line 26; and page 9, lines 3-16.	1-35
Y	BUDOWSKY et al. Principles of Selective Inactivation of the Viral Genome: Dependence of the Rate of Viral RNA Modification on the Number of Protonizable Groups in Ethyleneimine Oligomers. Vaccine Research. 1996, Vol. 5, No. 1, pages 29-39; especially the abstract; pages 29-30, "Introduction"; page 31, Fig.1; pages 34-36, "Discussion", first three paragraphs; and page 37.	1-35
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 05 JANUARY 2000	Date of mailing of the international search report <b>10 FEB 2000</b>	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>Brenda Brumback</i> BRENDA BRUMBACK Telephone No. (703) 308-0196	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/21245

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WAGNER et al. Approaches to the Reduction of Viral Infectivity in Cellular Blood Components and Single-Donor Plasma. Transfusion Medicine Reviews. January 1991. Vol. 5, No. 1, pages 18-32, especially page 24, the paragraph bridging columns 1 and 2 and pages 27-29, "Practical Implications..." in its entirety.	1-35
Y	GABLER, F.R. Cell Processing Using Cross-Flow Filtration. Developments in Industrial Microbiology. 1984, Vol. 25, pages 381-396, especially page 383 and 384, "Cell Harvesting".	12-17 & 24-33
Y	Database Derwent, Accession No. 92-413169/ 199250, RO 101400 A, CHIURCIU et al. 30 May 1991, see the entire document.	18-20
Y	SU 594771 A1 (ULUPOV et al.) 07 July 1993, English Translation, see the entire document.	18-20

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/21245

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

EAST: USPAT, EPO, JPO, Derwent; DIALOG: Medline, BIOTECH, Conf. Papers

search terms: ethyleneimine, azridine, oligomer, dimer, trimer, virus, viral, inactivat?, blood, cell, wash?, filter, filtration, quench?